Estrogen receptor beta activation prevents glucocorticoid receptor-dependent effects of the central nucleus of the amygdala on behavior and neuroendocrine function.
Neuropsychiatric disorders such as anxiety and depression have formidable economic and societal impacts. A dysregulation of the hypothalamo-pituitary-adrenal (HPA) axis leading to elevated endogenous glucocorticoid levels is often associated with such disorders. Chronically high glucocorticoid levels may act upon the central nucleus of the amygdala (CeA) to alter normally adaptive responses into those that are maladaptive and detrimental. In addition to glucocorticoids, other steroid hormones such as estradiol and androgens can also modify hormonal and behavioral responses to threatening stimuli. In particular, estrogen receptor beta (ERbeta) agonists have been shown to be anxiolytic. Consequently, these experiments addressed the hypothesis that the selective stimulation of glucocorticoid receptor (GR) in the CeA would increase anxiety-like behaviors and HPA axis reactivity to stress, and further, that an ERbeta agonist could modulate these effects. Young adult female Sprague-Dawley rats were ovariectomized and bilaterally implanted via stereotaxic surgery with a wax pellet containing the selective GR agonist RU28362 or a blank pellet, to a region just dorsal to the CeA. Four days later, animals were administered the ERbeta agonist S-DPN or vehicle (with four daily sc injections). Anxiety-type behaviors were measured using the elevated plus maze (EPM). Central RU28362 implants caused significantly higher anxiety-type behaviors in the EPM and greater plasma CORT levels than controls given a blank central implant. Moreover, S-DPN treated animals, regardless of type of central implant, displayed significantly lower anxiety-type behaviors and post-EPM plasma CORT levels than vehicle treated controls or vehicle treated animals implanted with RU28362. These results indicate that selective activation of GR within the CeA is anxiogenic, and peripheral administration of an ERbeta agonist can overcome this effect. These data suggest that estradiol signaling via ERbeta prevents glucocorticoid-dependent effects of the CeA on behavior and neuroendocrine function.
Weiser
Michael J
MJ
Department of Biomedical Sciences, Neuroscience Division, Colorado State University, Fort Collins, CO, USA.
Foradori
Chad D
CD
Handa
Robert J
RJ
D000679:Amygdala / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D001007:Anxiety / Q000378:metabolism*; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology*; D045166:Estradiol Congeners / Q000494:pharmacology; D047629:Estrogen Receptor beta / Q000378:metabolism*; D005260:Female; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000502:physiology; D007150:Immunohistochemistry; D009490:Neurosecretory Systems / Q000187:drug effects / Q000502:physiology*; D010052:Ovariectomy; D010913:Pituitary-Adrenal System / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011965:Receptors, Glucocorticoid / Q000378:metabolism*; D013315:Stress, Psychological
D045166:Estradiol Congeners; D047629:Estrogen Receptor beta; D011965:Receptors, Glucocorticoid
Endocrinology. 2005 Feb;146(2):797-807
15514081
Neuroendocrinology. 1993 Mar;57(3):517-24
8391664
Neuroscience. 1998 Sep;86(2):449-59
9881860
Annu Rev Neurosci. 1992;15:353-75
1575447
Brain Res. 1995 Feb 13;671(2):213-21
7743210
Psychoneuroendocrinology. 2008 Jul;33(6):773-81
18407426
Behav Brain Res. 2005 Jun 3;161(1):39-44
15904708
J Comp Neurol. 2006 Dec 20;499(6):911-23
17072840
Mol Endocrinol. 1990 Oct;4(10):1427-37
1704480
Front Neuroendocrinol. 2003 Jul;24(3):151-80
14596810
Eur J Pharmacol. 2008 Apr 7;583(2-3):255-62
18339373
Neuroscience. 1998 Jul;85(1):135-47
9607709
J Neuroendocrinol. 2004 Mar;16(3):272-8
15049858
Ann N Y Acad Sci. 1994 Nov 30;746:438-40
7825910
J Neuropsychiatry Clin Neurosci. 1997 Summer;9(3):382-402
9276841
Stress. 2002 Dec;5(4):235-47
12475728
J Comp Neurol. 1980 Nov 1;194(1):267-89
7440798
J Comp Neurol. 2001 Jul 16;436(1):64-81
11413547
Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12278-82
11593044
J Neuroendocrinol. 1994 Aug;6(4):433-42
7987374
J Biol Chem. 1983 Jan 10;258(1):417-25
6848510
J Comp Neurol. 1992 Oct 8;324(2):180-94
1430328
Neuroscience. 1998 Jun;84(4):1025-39
9578393
Eur J Neurol. 2007 Feb;14(2):e9
17250716
Exp Physiol. 1997 Mar;82(2):273-81
9129941
Brain Res Rev. 2008 Mar;57(2):309-20
17662459
Neurosci Res. 1996 Nov;26(3):235-69
9121734
Annu Rev Neurosci. 2004;27:193-222
15217331
Nature. 1986 Mar 13-19;320(6058):134-9
3754034
Pharmacol Biochem Behav. 2007 Feb;86(2):407-14
16916539
Horm Behav. 1994 Dec;28(4):464-76
7729815
Biol Psychol. 2001 Jul-Aug;57(1-3):141-52
11454437
Metabolism. 2005 May;54(5 Suppl 1):20-3
15877308
Physiol Rev. 2003 Jul;83(3):803-34
12843409
J Comp Neurol. 2005 Mar 28;484(1):28-42
15717309
J Neurosci Methods. 1985 Aug;14(3):149-67
2864480
Brain Res. 1994 Sep 26;658(1-2):21-6
7834344
J Pharmacol Toxicol Methods. 1993 Jun;29(3):129-38
8103377
Physiol Behav. 2005 Jan 31;84(1):157-63
15642619
J Neuroendocrinol. 2001 May;13(5):442-52
11328455
Endocrinology. 1985 Dec;117(6):2505-11
2998738
Brain Res Bull. 1994;35(4):379-82
7850490
Epidemiol Psichiatr Soc. 2009 Jan-Mar;18(1):23-33
19378696
Mol Endocrinol. 1996 Oct;10(10):1191-205
9121487
Neuroendocrinology. 1986;44(2):247-54
3025760
J Biol Chem. 1984 Jan 25;259(2):820-31
6693398
Brain Res Mol Brain Res. 1998 Feb;54(1):175-80
9526077
J Affect Disord. 2003 Mar;74(1):85-96
12646301
Brain Res. 1987 Mar 31;407(2):327-31
3567648
Behav Neurosci. 2008 Oct;122(5):974-81
18823154
Gen Pharmacol. 1990;21(1):83-7
2298391
Brain Res. 1994 Mar 21;640(1-2):105-12
8004437
Clin Exp Pharmacol Physiol. 1998 Oct;25(10):764-75
9784914
Psychoneuroendocrinology. 1996 Oct;21(7):609-20
9044444
J Comp Neurol. 1997 Dec 1;388(4):507-25
9388012
J Comp Neurol. 1989 Jul 22;285(4):413-35
2569487
Ann N Y Acad Sci. 1993 Oct 29;697:53-60
8257022
J Neurobiol. 1998 Sep 5;36(3):357-78
9733072
Horm Behav. 2004 Aug;46(2):158-64
15256305
J Comp Neurol. 2006 Jan 1;494(1):142-78
16304685
Brain Res. 2003 Feb 14;963(1-2):203-13
12560126
Brain Res. 2000 Apr 10;861(2):288-95
10760490
Physiol Behav. 1994 Feb;55(2):371-3
8153180
Brain Res. 1984 Jun 15;303(2):337-57
6204716
Science. 1954 Dec 3;120(3127):949-50
13216196
Gend Med. 2007;4 Suppl B:S178-93
18156102
J Comp Neurol. 1981 Nov 1;202(3):335-56
7298902
Neuropsychopharmacology. 2005 Sep;30(9):1598-609
15798780
Endocrinology. 2009 Apr;150(4):1817-25
19074580
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30
8650195
J Physiol. 1995 May 1;484 ( Pt 3):721-36
7623287
Pharmacol Biochem Behav. 1992 Oct;43(2):453-61
1438482
Brain Res Bull. 2007 Mar 15;71(5):466-74
17259015
Neuroscience. 2006 Sep 1;141(3):1503-15
16806720
Eur J Neurosci. 2001 Oct;14(7):1143-52
11683906
J Comp Neurol. 2004 Jan 6;468(2):277-98
14648685
Endocrinology. 1992 Sep;131(3):1261-9
1324155
Neuroendocrinology. 1989 Oct;50(4):433-46
2554178
Biol Psychiatry. 1998 Dec 15;44(12):1229-38
9861466
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3588-92
8386376
Nat Cell Biol. 2009 Sep;11(9):1093-102
19684579
J Neurosci. 2006 Feb 1;26(5):1448-56
16452668